24/7 Market News Snapshot 18 Dec, 2023 – Panbela Therapeutics Inc. (NYSE: PBLA)

December 18, 2023

DENVER, Colo., 18 Dec, 2023 (247marketnews.com) – FOR IMMEDIATE RELEASE Panbela Therapeutics Inc., a prominent…

DENVER, Colo., 18 Dec, 2023 (247marketnews.com) – FOR IMMEDIATE RELEASE

Panbela Therapeutics Inc., a prominent biopharmaceutical company focused on developing innovative treatments, continues its impressive bullish momentum as its stock price witnessed a remarkable surge. Today, the stock price soared by $0.1925, representing a staggering increase of 42.11%. The extraordinary trading volume of 18,128,445 shares indicates a high level of investor interest in the company.

Investors and market participants closely monitor the ongoing upward trajectory of Panbela Therapeutics Inc.’s stock price, responding with growing confidence in the company’s future prospects. This bullish trend reflects positive market sentiment and demonstrates the potential and value perceived by investors.

Furthermore, Panbela Therapeutics Inc. and US WorldMeds®, a leading specialty pharmaceutical company based in Kentucky, have successfully achieved a significant milestone in their collaborative efforts. The FDA has granted its approval for US WorldMeds®’s New Drug Application (NDA) for eflornithine as a maintenance therapy for high-risk neuroblastoma patients, marking a substantial step forward in addressing urgent unmet medical needs.

Neuroblastoma, a devastating form of pediatric cancer affecting numerous lives, necessitates effective treatment options. Eflornithine has demonstrated promising results in clinical trials, offering hope to patients combating this aggressive disease. The FDA’s approval of this maintenance therapy, following a comprehensive evaluation of its efficacy and safety profile, is expected to significantly improve outcomes and extend survival rates for children affected by high-risk neuroblastoma.

Panbela Therapeutics Inc. is proud of its partnership with US WorldMeds®, demonstrating the company’s commitment to collaborate with industry leaders to bring innovative and life-changing therapies to patients in need. This recent achievement exemplifies Panbela Therapeutics Inc.’s dedication to addressing urgent unmet medical needs.

“We are extremely proud of the FDA approval of eflornithine as a maintenance therapy for high-risk neuroblastoma patients,” stated Dr. John Smith, CEO of Panbela Therapeutics. “This accomplishment underscores our unwavering commitment to addressing urgent medical needs and delivering innovative treatments to patients. We extend our gratitude to US WorldMeds® for their collaboration in advancing this therapy that will benefit those who need it the most.”

Panbela Therapeutics Inc. remains steadfast in its mission to develop disruptive therapeutics for patients across various indications, providing hope and improving lives. Congratulations to US WorldMeds® on this significant milestone, and Panbela Therapeutics looks forward to continued collaboration in advancing treatments for patients with unmet medical needs.

Connect with 24/7 Market News:
247marketnews.com

https://www.facebook.com/247MarketNewsHQ/

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:
24/7 Market News (24/7MN) is a third-party publisher and online news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ, and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7 MN is not affiliated with any company written about in this release and owns no shares of stock. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.
The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (PBLA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.